On 16 November 2005, we celebrated the milestone when 10 million donors had been registered in Bone Marrow Donors Worldwide (BMDW). Since then another million donors have been added in little more than a year. It seems an appropriate time for reassessment and to ask whether we are on the right track or not. We will do so by discussing the strength, weaknesses, opportunities and threats of the unrelated stem cell donor operation.
A bit of history
It was in 1964, now over 40 years ago, that a patient's life was saved for the first time thanks to our-at that time rudimentary-knowledge of human leucocyte antigen (HLA). It concerned a 42-year-old, multiparous woman, suffering from a chloramphenicol-induced bone marrow aplasia, who was admitted to the Leiden University Hospital, because of life-threatening bleeding from all orifices. She was initially treated with platelet concentrates from randomly selected blood donors, at that time a brand new form of treatment. These transfusions were able to stop bleeding for about a month, but then leucocyte antibodies appeared in her serum impairing platelet recovery after transfusion to near zero and she started to bleed again. Fortunately, she had a large number of siblings from which HLA compatible donors could be selected. Their platelets had again a good recovery and after 3 months of HLA-matched platelet support the bone marrow aplasia disappeared and she made a full recovery. 1 In 1968, our group in Leiden and Robert Good's group in Minneapolis knew enough about HLA matching to make it possible for the first time to select HLA-identical sibling bone marrow donors for three patients suffering from congenital immune deficiencies. All three patients were cured by their sibling donor transplants. 2 It was soon realised that only one out of three patients had an HLAidentical sibling donor, and in 1970 it was proposed to start an European file of HLA typed blood transfusion donors, named Europdonor, to help patients in need of HLA-matched platelets or bone marrow, but without an HLA-identical sibling donor. The idea did not catch on in the other European countries at that time, but Europdonor has been functioning in The Netherlands since 1970, mainly by providing HLA-matched platelets, and occasionally HLA-matched unrelated bone marrow. [3] [4] [5] In 1974, Shirley Nolan started what is now the Anthony Nolan Trust to find a donor for her son suffering from Wiskott-Aldrich syndrome. 'The Nolan' became the first registry of unrelated bone marrow donors routinely providing bone marrow first in the UK and soon all over the world. 6 In the 1980s, other European countries and the USA followed this example. By 1988, there were eight active registries with together 150 000 donors. Finding a suitable donor in the pre-Internet time was cumbersome and time-consuming and the proposal to start a listing of the HLA phenotypes, Bone Marrow Donors Worldwide (BMDW), was soon accepted. 7 In 1993, Pablo Rubinstein started collections of cord blood units in the first Cord Blood Bank at the New York Blood Center (NYBC) and issued the grafts for the first two matched, unrelated cord blood transplants. 8 The number of registries and donors continued to grow. Today over 11 million bone marrow donors and cord blood units from 58 registries and 36 cord blood banks are available to provide life-saving stem cells to patients in need of them and can easily be contacted through BMDW. 9 
Strength
There is no doubt that our strength lies with these millions of donors: they are a symbol of hope and testamonial to the goodwill to people in the world united in their effort to provide life-saving help to those who need it. That is our strength. Without these donors we, the registries and cord blood banks, would not exist.
Every country celebrated 16 November 2005 in its own way. In France, donors from different countries discussed how they felt about being a donor, in the USA donors and recipients met, and in Cyprus the prime minister proclaimed that the 10 millionth donor came from Cyprus, and why not?
Since 1997, the World Marrow Donor Association (WMDA) has made annual reports recording the number of unrelated stem cell donations, which makes quite interesting reading. Figure 1 shows that since 1997, stem cell donations have tripled, peripheral blood stem cell donations have become increasingly popular and that since 2003 cord blood transplants have doubled. 10 The fact that the number of transplants tripled implies that many patients-today qualifying for a stem cell transplant-did not get one in previous years. Of course indications for transplantation have increased significantly, but it remains an open question whether we are now providing a transplant to every patient in need of one. We will return to this point later on.
Fortunately the great majority of these stem cell donations occur without complications but the WMDA 
Weaknesses
The large number of donors is our strength and we stand in debt to them, but what are our weaknesses? Our prime and most serious weakness is that in the period 2000-2006, out of about 151 000 patients qualifying for an HLA unrelated donor (UD) transplant, only 64 720 received one. Figure 2 shows not only the transplants realised, the light grey bars, but also the number of patients looking for a donor. 10 Overall there is almost a three-fold difference. Clearly we must try to do better. Fortunately many of these patients had other options, such as an autologous or haploidentical transplant, but that does not take away the fact that they were opting for an UD and this did not materialise.
Why do almost two thirds of the patients not reach transplantation? Many causative factors can be identified. In the first place, the search process is overall much too slow. If we take Europdonor as an example, Heemskerk et al. 11 showed that for 30% of the patients, our search process and work-up for transplantation takes so much time, that when finally a donor has been located and found to be fit for donation, the patient has relapsed or is otherwise unfit for transplantation. As the average search time of Europdonor and patient work-up time in the Dutch transplant centres (TCs) is about the same as other registries, who have reported on this, there is a priori no reason to assume that the situation outside Europdonor is much different and very few registries provide blood samples for confirmatory high resolution typing within 15 working days, as recommended by WMDA. 12 The enormous polymorphism of HLA is a second reason why only one out of three patients reaches transplantation. Even with our 11 million donors, only two out of three Caucasoid patients will find a 10 out of 10 HLA allelematched donor; and for other racial groups, it can be as low as one out of four. 13 Unfortunately, there is still a sizeable number of TCs that insist on the availability of a 10 out of 10 HLA-matched donor before considering proceeding to transplantation. Of course, every transplant centre is and should be free to make its own rules, but one should realise that a graft with one or even more allele Class I mismatches still can lead to a survival at 9 years post-transplant of 25%, which compares favourably with death, a definitive certainty without alternative therapy 14, 15 ( Figure 3) .
The transplant results are improving over the years, but it does so much more slowly than what has been achieved in organ transplantation. We should also remember that we have to try to match for all loci thus not only for HLA-A, -B and -DRB1, but also HLA-C, and perhaps -DQ and -DP, which now also are believed to influence graft prognosis. [14] [15] [16] That is certainly not all. A milestone paper by Kawase et al. 17 reporting on a study of over 5000 HSCT's performed in Japan show that certain amino acid substitutions influence stem cell transplant outcome unfavourably. Apart from the importance of incompatibilities at certain amino acid positions, [17] [18] [19] additional loci in and outside HLA and KIR haplotype matching influence stem cell transplant outcome. [20] [21] [22] We certainly need a major effort to match for all these loci.
In the third place, the cost of finding an unrelated donor (UD) and obtaining the stem cells can preclude transplantation. It starts with the confirmatory typing (CT) samples, next when a donor is found the harvest costs, which vary from 12 000 to 25 000 Euro, with the cord bloods from 9000 to over 25 000 Euro and finally the transportation costs. The total costs can vary between 13 000 and 30 000 Euro; for quite a few patients or their insurance company this is a 'bridge too far'. These are estimates. The real costs in the different countries are largely unknown, 23 but they form a barrier to transplantation for many patients. By identifying the real cost elements we might be able to reduce them.
One final and serious weakness is that the BMDW search operation has become outdated. When we started in 1988, there were eight registries with together in total no more than 150 000 donors. There are now 11 million donors and cord blood units in nearly 100 registries and cord blood banks. For about half of our Caucasoid patients, 20 or more HLA-A, -B and -DR split level identical donors spread out in these organisations are available. And one quarter of our patients have 100 or more split level matched HLA-identical donors! (H.G.M. van der Zanden, personal communication). Selecting a young (male) donor with the right cytomegalovirus (CMV) status for a given patient can have a major and favourable impact on transplant outcome. 24, 25 How can one select quickly the most appropriate donor for a given patient without having information on age, gender, CMV status upfront in BMDW? We are in fact back to where we were in 1988! Unfortunately the Editorial Board (EB) of BMDW has as yet not been able to work out how this information can be implemented in BMDW without jeopardising donor confidentiality and registries logistics. The EB has here an important and urgent task to resolve.
Opportunities
How can we improve our operation? Fortunately, we have many opportunities to improve access and results and to reduce the costs. Registries, search co-ordinators and TCs each can make an important contribution to this end.
A logical and important first question to be asked by the registries is-considering the fact, that even Caucasoid patients have only a 60% chance of finding a 10 out of 10 allele HLA-matched donor-whether we need more donors? The answer is 'yes and no'. Of course, of young, preferably male donors, one never has enough! They should be targeted as replacement of the donors who retire because of old age or for other reasons. The registries can make an important contribution to speeding up the search process by typing up-front newly recruited donors at high resolution for HLA-A, -B, -C and -DRB1.
Because of different logistic reasons almost 20% of the registries have typed a large part of their donors for HLA-A and -B only. There are in total three million of such donors in BMDW, who are almost never used. Such registries can speed up the search process further by contacting those of these donors, who have a relatively low frequency HLA-A and -B phenotype and are not yet too old. If they confirm their willingness to donate stem cells, they could be retyped at high resolution for at least HLA-A, -B, -C and -DRB1.
As far as increasing the number of available phenotypes is concerned, increasing the number of donors is not costeffective anymore if one recruits donors from a population with a NW European background. The frequent phenotypes are all there and in abundance and the so-called unique phenotypes, which one lacks, have a frequency of less than one in 11 million donors. 26 For populations with a different racial background than the NW European one, we certainly need more donors, but these can for logistic reasons most efficiently be recruited via cord blood collection. 8 As we just discussed, one of our major weaknesses is that it takes too long before a donor is selected, tested and the pre-transplant work-up of the patient is completed. Figure 4a shows the ED search time span data. 11 There is certainly an improvement during the last decade in the search time to locate a donor. However, after a donor has been selected, it takes also in The Netherlands an additional 2 months before the patient gets transplanted (Figure 4b) . It must be possible to reduce the overall time quite substantially with no more than some clear guidelines between registries and TCs.
There is of course also a contradiction in Figures 4a and b. We and others have proudly published case histories, in which-because for example of accidental non-availability of bone marrow, while the patient had already been conditioned with a lethal dose of irradiation-we found, tested and collected the bone marrow from another donor within 7 days or even less! 27 (S Cleaver, personal communication). The authors are birds of many feathers and we have in our background a blood banker's career (and blood banks run 7 days a week at 24 h service) and organ transplantation (and if a multi-organ donor becomes available, the heart and the liver and sometimes the kidneys are transplanted within 12 h) and we are taking the liberty of wondering whether we-in the registry world-should not rethink our logistics of the donor search and routinely try to locate the best donor within weeks instead of months. As a consequence, the costs may rise further, but it would save lives. 11 This makes of course no sense if the TC cannot speed up their part of the operation as well.
These are easy, general statements and it will take quite some time before they can be implemented. However, there are quite a number of actions we can activate right now. In the first place, the transplant co-ordinators can make an important contribution by using BMDW up front for each and every search. It is done already by most search coordinators, but unfortunately not by all. If it is clear that a 10 out of 10 HLA-identical donor is not available, then accept that fact, do not lose time by looking for something which you know is not available, and go for an alternative. This can be a one or two allele-mismatched donor, a cord blood or a haploidentical donor.
If you select an allele-mismatched donor, you have the option to try to find out one with a negative cytotoxic T-lymphocyte precursor (CTLp) test. It has been shown that the CTLp tests, although difficult to perform and expensive, can discriminate between harmful and acceptable mismatches as illustrated in Figure 5 . 19 A total of 53 patients with a single class I mismatched donor could be divided in a group with a negative CTLp test and a survival of over 60% at 7 years post-transplant, while survival was only 20% when the CTLp test was positive. 19 Another way to effectively prevent delay before the transplant is the back-up donor. Van Walraven et al. 28 have
shown that if a back-up donor is available, delay to transplant is only 7 days if the first choice donor is unable to donate, while without a back-up donor it is on average 79 days ( Table 2 ). Note that 11% of the first choice donors can in the end not donate! If a patient needs a transplant urgently and/or no 10 out of 10 donor is available, cord bloods can be very helpful and most importantly can save time. The two recent papers from the Center for International Blood and Marrow Transplant Research (CIBMTR)/New York Blood Center (NYBC) and EuroCord in the New England Journal of Medicine both made it clear that cord blood transplants even with one or more HLA-A, -B, -DRB1 mismatches (note: at the antigen level for -A and -B and only at allele level for HLA-DRB1) can give an adult patient a survival expectancy which is really not much worse than that of matched bone marrow donors 29, 30 ( Figure 6 ). As reported by Brunstein et al. 31 double cord blood transplants might be even able to improve on this. Many Cord Blood Banks have followed the example of the National Cord Blood Program of the NYBC (NCBP-NYBC) and make a special effort to store cord bloods from minority group donors, which are underrepresented in the registries. 8 This can have a major impact on the ability to provide stem cell transplants to patients from minority groups as illustrated in Table 3 . In this table, the performances in the year 2002 of the NYBC and the National Marrow Donor Program (NMDP) are compared for their ability to provide stem cells to minority group patients. It is clear that the NYBC with, at that time, less than 40 000 cord blood units in stock, could provide grafts to a larger percentage of patients from minority groups than the NMDP with over four million donors. This is due not only to the advantage of cord blood HLA matching (for A and B at the antigen level and only for DRB1 at the allele level), but also reflects the relatively high numbers of unique HLA phenotypes present in cord blood banks as compared to registry donors. 8, 9 The NMDP has since recruited over 50 000 cord blood units in order to be better able to provide stem cells to minority group patients. 1 Many TCs follow nowadays a three line approach, if a patient is in urgent need of a transplant: not only is a suitable stem cell donor and/or cord blood looked for in BMDW, but also at the same time it is checked whether a suitable haploidentical family donor might be preferable. We will restrict our discussion on this issue to the haploidentical transplant with T-cell replete stem cells. This is possible because there is strong evidence that during pregnancy, a two-way exchange of cells between mother and child and vice versa takes place, which results in a sizeable likelihood of both mother and child acquiring a life-long partial tolerance to the other.
And this opens the possibility to perform T-cell replete stem cell transplants from mother to child, child to mother and between haploidentical sibling-to-sibling using standard conditioning and graft-versus-host disease (GVHD) prophylaxis.
A new HLA haplotype nomenclature is helpful in discussing these data ( Figure 7) . The child has inherited the maternal and paternal antigens from the parents respectively the IMAs and IPAs. It has not inherited the non-inherited maternal antigens (NIMAs), but it has been (through chimaerism) in contact with these antigens. Likewise, the mother has been in contact with IPAs of the child. If the mother donates to the child the GVH reaction will be directed to the IPA, when the child donates to the mother the GVH reaction will be directed to the NIMA. Likewise, haploidentical sibling transplants will only be done when the mismatch is NIMA-directed.
T-cell replete, one or two loci-mismatched haploidentical transplants between NIMA-mismatched siblings had less acute and chronic GVHD than a transplant from a noninherited paternal antigens (NIPA)-mismatched sibling-tosibling transplant or mother or father to child transplant. Although the GVHD is less in NIMA-mismatched siblingto-sibling transplants, it is still increased as compared to HLA-identical sibling transplants (Figure 8) . 32 Especially, in Japan, the experience with transplants using this alternative group of donors is now accumulating.
33,34
The results with the mother as donor or as recipient (a new feature) are especially interesting. Transplants from mother to child, that is with an IPA mismatch, give more severe GVHD than child to mother or sibling-to-sibling NIMA-mismatched grafts. But for the whole group, if mutual chimaerism is present, overall survival after 2 years for those Japanese patients who were transplanted in remission was 60%, while for those who were refractory to therapy or in relapse survival was still 20% after 2 years ( Figure 9 ).

Threats
The short-term future of the donor registries and cord blood banks is not at risk. They fulfil a need and complement each other. This does not mean however that we can sit back and relax. As discussed earlier and below, there are many aspects of the operation, which need our attention and can be improved. The difficulty is that so many independent organisations are involved. The WMDA has done and is doing a wonderful job as far as accreditation, regulations and ethics guidelines are concerned. The main difficulty lies in the fact, that there are so many independent registries and cord blood banks. Priorities of very large registries are quite different from those of the smaller ones, often working with one or a few TCs. However, even the largest registries are dependent on the 'import' of donors sometimes from quite small registries for a sizeable fraction of their national patients. In other words, there is a need for both the small and large registries. We have discussed above the importance of selecting a donor with the right gender for a given patient, as young as possible and with the right CMV status. This is at the moment almost impossible to achieve, especially if 20 donors, in many different registries, are available, which is the case for half of our patients. The situation is further complicated by the fact that virtually all registries are dependent on their quantitative performance, that is the number of stem cell donations they realise to keep their budgets solvent. This can create conflict of interest, certainly when the operation is small and the co-ordinators of registry and transplant centre are one and the same person or two very closely collaborating individuals. As long as all donors in BMDW do not show all the abovementioned information and/or are not typed for 10 loci at high resolution, it will be next to impossible to establish whether you have selected the best donor or not.
Since 1997, WMDA has been able to keep an almost complete track of unrelated stem cell and cord blood donations worldwide, but what happened to the patients who received these stem cells is only known in part. Some estimate the fraction of patients transplanted with an HSCT and with an adequate follow-up as in the order of less than 70% and then often with incomplete and near useless information as far as HLA is concerned (M Horowitz, personal communication). This is shameful and unacceptable for a therapy that is not only quite expensive and only partially successful, but also not without risk to the volunteer donors. WMDA, European Group for Blood and Marrow Transplantation (EBMT) and CIBMTR must all make a concerted effort to improve logistics and the reporting of transplant outcome. The transplant centre coordinators can contribute to this substantially by providing high-resolution typing data of the donor and the patient as well as age, gender and CMV status soon to be complemented by information on minor histocompatibility antigens and killer cell immunoglobulin-like receptor (KIR) typing. In this context, it might be worthwhile to study the possibility to use the software of the European Marrow Donor Information System (EMDIS), which has facilities to store the final HLA typing data of both patient and donor. An online transfer of these data to the EBMT and CIBMTR files would assure an easy and reliable sharing of information which is crucial for follow-up studies.
Another aspect of the operation, which is rarely discussed, concerns the question: 'Who is here in control'? One can question whether the continuous growth of millions of donors with a total cost of already now well over 3 billion Euro is really a good thing or are there 35 Unfortunately, they are the exception. In many registries, the comparison with the 'Sorcerer's Apprentice' opera is valid: donor recruitment is decentralised, often emotionally based and many of the recruited donors withdraw when actually confronted with a donation request. WMDA has in this context another educational task to deal with.
Looking at the annual WMDA reports, it is clear that we are witnessing a shift from the use of bone marrow donors to cord blood. At the moment cord blood's, major handicap is that if the patient has relapsed donor lymphocyte infusions are not possible. At least not yet! Protocols are in progress to resolve this, but that may take time.
There is another trend which is complicating the picture further, that is the storage of cord blood for autologous use. Started as a deplorable, money-making business, it has caught the public's eye and at this moment the number of cord blood units in storage for autologous use is two-to three-fold that of the public banks. And it is steadily increasing.
Autologous cord blood has been used occasionally, although the chance that the donor ever needs his or her own cord blood for a valid medical reason is small and probably less than 1 in 10 000. In Spain, autologous cord blood storage was forbidden by law, but this has been recently changed (M Fernandez, personal communication). It is now allowed under the following conditions:
1. The storage should be done following state-of-the-art guidelines. 2. HLA typing should be performed and reported to a certified public bank. 3. If a patient is in need of such an autologous stored cord blood (s)he has priority over the donor. In that case, the donor's family is reimbursed for the costs.
These are all very recent and interesting developments, which, in the end, result in the transfer of the cost of public banking to over-anxious parents of new and future babies. Time is required to conclude whether they are an improvement or not. Whatever the case, it is clear that such a strategy should be based on globally accepted ethics and regulation.
Concluding remarks
If we look at what has been achieved in the last 40 years in stem cell transplantation, it is clear that enormous progress has been made. It is equally clear that stem cell transplantation is still a half way technique, since it is not yet available to the majority of patients in need and it needs further improvement, or replacement (such as has been achieved by imatinib for chronic myeloid leukaemia). One of the major obstacles to further progress is that the number of transplants annually performed is relatively small, particularly, if we take into account the heterogeneity of the patient population as far as diagnosis, stage of disease and age are concerned. The situation is further complicated by the fact that these transplants are performed in hundreds of autonomous TCs. They collaborate in case-controlled studies as well in an increasing number of randomised prospective trials, but these rarely address major issues such as a randomised prospective trial of bone marrow versus PBSC versus cord blood transplantation with one or two donors. Another weak point is that most follow-up studies start at the moment when an intention to treat, that is stem cell transplantation has been decided upon, while it is more relevant to start a follow-up study of the therapy of a disease at the time of diagnosis.
Patients and their families have influenced the development of stem cell transplantation in a strong and positive manner beginning with Shirley Nolan and followed by Fred Hutchinson, Jose Carreras, Peter Harf and many others. There is no other form of treatment in which the family is so directly and physically involved as stem cell transplantation. The Internet has made family members well informed and often solid partners in our efforts to improve our results. They deserve to be involved in our planning for the future and decision making.
